Research Article
The Relationship of Antibodies to Modified Citrullinated Vimentin and Markers of Bone and Cartilage Destruction in Rheumatoid Arthritis
Table 2
Characteristics of RA patients depending on the level of positivity for anti-MCV, Me (IQR).
| | Parameters | High-positive anti-MCV (>60.0 U/mL) () | Negative/low-positive anti-MCV (≤60 U/mL) () | |
| | Age, years | 53.5 (44.5–62.5) | 48.0 (35.5–59.0) | >0.05 | | Disease duration, months | 60.0 (28.5–111.0) | 72.0 (33.0–121.0) | >0.05 | | Number of females/males | 62/17 | 24/3 | >0.05 | | DMARD use (MTX/other DMARDs), % | 79.7/13.9 | 81.5/18.5 | >0.05 | | DAS 28 | 5.9 (5.1–6.7) | 5.8 (5.1–6.4) | >0.05 | | ESR, mm/hr | 40.0 (30.0–61.0) | 30.0 (21.0–48.5) | 0.02 | | CRP, mg/L | 23.1 (12.4–48.2) | 18.4 (10.5–37.0) | >0.05 | | COMP, ng/mL | 485.0 (405.0–655.0) | 340.0 (270.0–535.0) | 0.02 | | Elevated levels of MMP-3, % | 56.0 | 31.0 | 0.038 | | Negative/low-positive IgM RF, (%) | 14 (17.7) | 15 (55.6) | <0.01 | | High-positive IgM RF, (%) | 65 (82.3) | 12 (44.4) | <0.01 | | Negative/low-positive anti-CCP, (%) | 4 (5) | 19 (70.4) | <0.01 | | High-positive anti-CCP, (%) | 75 (95) | 8 (29.6) | <0.01 | | Joint space narrowing (JSN) | 82.0 (60.0–105.0) | 50.0 (29.0–82.0) | <0.01 | | Total modified Sharp score (mTSS) | 96.5 (65.0–122.0) | 57.0 (31.0–88.0) | <0.01 |
|
|
